The COVID-RASi study is an international randomized clinical trial that will evaluate the
potential benefit of angiotensin modulators on clinical outcomes, in COVID-19 patients who
are at high-risk for cardiovascular disease. The purpose of this study is to determine if
renin-angiotensin system inhibitors (RASi), with angiotensin-converting enzyme inhibitors
(ACEi) or angiotensin II receptor blockers (ARB), has a beneficial effect in high-risk older
patients with COVID-19 infections, by reducing ICU admission, ventilator requirement or
death. We would also like to determine if there are differences between ACEi and ARB
therapeutic treatments.